Mass budgets of the Lambert, Mellor and Fisher Glaciers and basal fluxes beneath their flowbands on Amery Ice Shelf

We used in situ measurements and remote-sensing data sets to evaluate the mass budgets of the Lambert, Mellor and Fisher Glaciers and the basal melting and freezing rates beneath their flowbands on the Amery Ice Shelf. Our findings show the Lambert and Mellor Glaciers upstream of the ANARE Lambert Glacier Basin (LGB) traverse may have positive imbalances of 3.9±2.1 Gt a−1 and 2.1±2.4 Gt a−1, respectively, while the Fisher Glacier is approximately in balance. The upstream region as a whole has a positive imbalance of 5.9±4.9 Gt a−1. The three same glaciers downstream of the ANARE LGB traverse line are in negative imbalance, where the whole downstream region has a negative imbalance of −8.5±5.8 Gt a−1. Overall the mass budgets of the Lambert, Mellor, and Fisher Glaciers are close to balance, and the collective three-glacier system is also nearly in balance with a mass budget of −2.6±6.5 Gt a−1. The significant positive imbalances for the interior basin upstream of the ice-movement stations established in the early 1970s (GL line) reported previously are possibly due to an overestimate of the total accumulation and an underestimate of the ice flux through the GL line.The mean melting rate is −23.0±3.5 m ice a−1 near the southern grounding line, which decreases rapidly downstream, and transitions to refreezing at around 300 km from the southern extremity of the Amery Ice Shelf. Freezing rates along the flowbands are around 0.5±0.1 to 1.5±0.2 m ice a−1. The percentage of ice lost from the interior by basal melting beneath the flowbands is about 80%±5%. The total basal melting and refreezing beneath the three flowbands is 50.3±7.5 Gt ice a−1 and 7.0±1.1 Gt ice a−1, respectively. We find a much larger total basal melting and net melting than the results for the whole Amery Ice Shelf derived from previous modeling and oceanographic measurements

Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C

BACKGROUND: There is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection or limits in vivo viral replication. The objective of these studies is to develop a replication-competent, vaccine vector based on the adenovirus serotype 4 (Ad4) virus expressing HIV-1 envelope (Env) 1086 clade C glycoprotein. Ad4 recombinant vectors expressing Env gp160 (Ad4Env160), Env gp140 (Ad4Env140), and Env gp120 (Ad4Env120) were evaluated. METHODS: The recombinant Ad4 vectors were generated with a full deletion of the E3 region of Ad4 to accommodate the env gene sequences. The vaccine candidates were assessed in vitro following infection of A549 cells for Env-specific protein expression and for posttranslational transport to the cell surface as monitored by the binding of broadly neutralizing antibodies (bNAbs). The capacity of the Ad4Env vaccines to induce humoral immunity was evaluated in rabbits for Env gp140 and V1V2-specific binding antibodies, and HIV-1 pseudovirus neutralization. Mice immunized with the Ad4Env160 vaccine were assessed for IFNγ T cell responses specific for overlapping Env peptide sets. RESULTS: Robust Env protein expression was confirmed by western blot analysis and recognition of cell surface Env gp160 by multiple bNAbs. Ad4Env vaccines induced humoral immune responses in rabbits that recognized Env 1086 gp140 and V1V2 polypeptide sequences derived from 1086 clade C, A244 clade AE, and gp70 V1V2 CASE A2 clade B fusion protein. The immune sera efficiently neutralized tier 1 clade C pseudovirus MW965.26 and neutralized the homologous and heterologous tier 2 pseudoviruses to a lesser extent. Env-specific T cell responses were also induced in mice following Ad4Env160 vector immunization. CONCLUSIONS: The Ad4Env vaccine vectors express high levels of Env glycoprotein and induce both Env-specific humoral and cellular immunity thus supporting further development of this new Ad4 HIV-1 Env vaccine platform in Phase 1 clinical trials